
Malaria
Learn about the mosquito-transmitted disease, which kills over one million per year, most of them children.
The disease chiefly affects lowland tropical regions, where conditions favor Anopheles mosquitoes, which carry the malaria parasite plasmodium. It's the blood-seeking females that inject these microscopic invaders, each bite acting like an infected hypodermic needle.
Of the four kinds of plasmodia, Plasmodium falciparum is by far the most dangerous, responsible for about half of all malaria cases and 95 percent of deaths. Parasite
The parasite has a complicated life cycle, which begins in the mosquito's gut before moving to the salivary glands, where it awaits transfer to the next host. Once in a human's bloodstream, the parasite lodges in the liver, burrowing into cells where it feasts and multiplies. After a week or two the plasmodia burst out—around 40,000 replications for each parasite that entered the body. Next they target red blood cells, this time repeatedly, until there are billions of parasites in circulation. If this cycle isn't checked, the body starts to fail, because with so many oxygen-carrying red cells being destroyed there are too few left to sustain vital organs. Meanwhile, all it takes for the parasite to pass on its grim legacy is for another mosquito to stop off for a meal.
Almost two-thirds of humans infected live in sub-Saharan Africa, which also bears around 90 percent of the global malaria death toll. A child there dies from the disease about every 30 seconds. Elsewhere, countries worst affected are in southern Asia and Latin America.
Those most vulnerable are young children, who have yet to develop any resistance to the disease, and pregnant women who have reduced immunity. Signs of infection include flu-like symptoms such as fever, shivering, headache, and muscle ache. The P. falciparum parasite can lead to life-threatening conditions such as brain damage (cerebral malaria), severe anemia, and kidney failure. Survivors are often left with permanent neurological damage.
For centuries the only widely known malaria remedy was quinine, which came from the bark of the cinchona tree of Peru and Ecuador. Then, in the 1940s, a synthetic drug was created using the compound chloroquine. Around the same time, the insecticide known as DDT was developed. These twin weapons led to a worldwide assault on malaria, eradicating the disease in many areas, including the United States and southern Europe.
But malaria has made a major comeback since the 1970s, partly because DDT use was severely restricted after it was found to be harmful to certain wildlife, and because the plasmodium parasite started becoming resistant to anti-malaria drugs.
With more people now falling sick from malaria than ever before, the need to tackle it has never been so urgent. The top priority, health experts say, is finding a vaccine—seen as the only surefire way of beating the disease. Peekaboo American mosquito nets (left) afforded explorers better vision and ventilation than English ones (right). That's according to the 1926 National Geographic article in which this photo appeared, which chronicled an exploration of the Amazon Valley. Photograph by Albert W. Stevens, Nat Geo Image Collection

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29-07-2025
- Yahoo
Scientists are studying ways to make your blood deadly to mosquitos
A new study in the New England Journal of Medicine has found that ivermectin, an antiparasitic drug used to treat tropical diseases such as river blindness, can also fight the spread of malaria. It does so in a way that seems oddly (and satisfyingly) like revenge against the mosquitos that carry the disease. It makes the user's blood a deadly poison to the insects that want to consume it. The new study, Ivermectin to Control Malaria — A Cluster-Randomized Trial, published this month, found that malaria cases dropped by 26 per cent in those who took the medication monthly. Researchers also noted a drop in cases of lice, scabies and bedbugs among participants in the trial. The study, led by the Barcelona Institute for Global Health, took place in Kwale, a county in coastal Kenya that has a high rate of malaria in spite of such techniques as the use of insecticide-treated nets. Clusters of household areas were assigned to receive mass administration of ivermectin for three months beginning at the start of the rainy season. Children aged 5 to 15 were then tested for malaria infection monthly for 6 months after the first round of treatment. 'Among children 5 to 15 years of age who were living in an area with high coverage and use of bed nets, ivermectin, administered once a month for three consecutive months, resulted in a 26 per cent lower incidence of malaria infection than albendazole (the control drug),' the researchers wrote. They added: 'No safety concerns were identified.' The researchers note that there were 249 million cases of malaria and 608,000 malaria-related deaths in 2022 alone. 'Interventions targeting the vector, such as long-lasting insecticide-treated nets or indoor residual spraying, remain the cornerstone of malaria control and are responsible for the estimated 81 per cent reduction in disease burden seen in Africa between 2000 and 2015,' they note. ('Vector' refers to an insect such as a mosquito that transmits a disease such as malaria.) 'However, progress has stalled in recent years (due to) emerging resistance to insecticides and behavioural adaptations, such as outdoor and crepuscular biting.' Ivermectin isn't the only drug being tested as a way to kill mosquitoes with the very thing they feed on. Another recent study investigated the effects of nitisinone, a drug used to treat rare metabolic disorders. 'The authors show that nitisinone targeted a crucial enzyme that mosquitoes need to digest their blood meal,' those researchers write. 'When female Anopheles mosquitoes in the laboratory consumed blood containing nitisinone, the drug was lethal to young, old, and insecticide-resistant populations and outperformed the mosquitocidal drug ivermectin. Even at low therapeutic doses, nitisinone remained deadly to mosquitoes. These findings warrant further investigation of nitisinone for vector control and the prevention of malaria transmission.' Mosquito season is worse this year, but TikTok user says she has a solution How to protect yourself from mosquitoes and West Nile virus Our website is the place for the latest breaking news, exclusive scoops, longreads and provocative commentary. Please bookmark and sign up for our newsletters here.


National Geographic
17-07-2025
- National Geographic
Malaria
Anopheles Mosquito Her abdomen full of blood that will nourish her eggs, a femaleAnopheles mosquito takes to the air. Her next landing may be a dangerous one—for the human who receives her bite. The female Anopheles mosquito is the only insect capable of carrying the human malaria parasite. Photograph by Hugh Sturrock Learn about the mosquito-transmitted disease, which kills over one million per year, most of them children. The disease chiefly affects lowland tropical regions, where conditions favor Anopheles mosquitoes, which carry the malaria parasite plasmodium. It's the blood-seeking females that inject these microscopic invaders, each bite acting like an infected hypodermic needle. Of the four kinds of plasmodia, Plasmodium falciparum is by far the most dangerous, responsible for about half of all malaria cases and 95 percent of deaths. Parasite The parasite has a complicated life cycle, which begins in the mosquito's gut before moving to the salivary glands, where it awaits transfer to the next host. Once in a human's bloodstream, the parasite lodges in the liver, burrowing into cells where it feasts and multiplies. After a week or two the plasmodia burst out—around 40,000 replications for each parasite that entered the body. Next they target red blood cells, this time repeatedly, until there are billions of parasites in circulation. If this cycle isn't checked, the body starts to fail, because with so many oxygen-carrying red cells being destroyed there are too few left to sustain vital organs. Meanwhile, all it takes for the parasite to pass on its grim legacy is for another mosquito to stop off for a meal. Almost two-thirds of humans infected live in sub-Saharan Africa, which also bears around 90 percent of the global malaria death toll. A child there dies from the disease about every 30 seconds. Elsewhere, countries worst affected are in southern Asia and Latin America. Those most vulnerable are young children, who have yet to develop any resistance to the disease, and pregnant women who have reduced immunity. Signs of infection include flu-like symptoms such as fever, shivering, headache, and muscle ache. The P. falciparum parasite can lead to life-threatening conditions such as brain damage (cerebral malaria), severe anemia, and kidney failure. Survivors are often left with permanent neurological damage. For centuries the only widely known malaria remedy was quinine, which came from the bark of the cinchona tree of Peru and Ecuador. Then, in the 1940s, a synthetic drug was created using the compound chloroquine. Around the same time, the insecticide known as DDT was developed. These twin weapons led to a worldwide assault on malaria, eradicating the disease in many areas, including the United States and southern Europe. But malaria has made a major comeback since the 1970s, partly because DDT use was severely restricted after it was found to be harmful to certain wildlife, and because the plasmodium parasite started becoming resistant to anti-malaria drugs. With more people now falling sick from malaria than ever before, the need to tackle it has never been so urgent. The top priority, health experts say, is finding a vaccine—seen as the only surefire way of beating the disease. Peekaboo American mosquito nets (left) afforded explorers better vision and ventilation than English ones (right). That's according to the 1926 National Geographic article in which this photo appeared, which chronicled an exploration of the Amazon Valley. Photograph by Albert W. Stevens, Nat Geo Image Collection


Time Business News
16-07-2025
- Time Business News
Innovative Frontiers in Artemisinin Combination Therapy
To increase efficacy and reduce the risk of drug resistance, artemisinin combination therapy (ACT) treats malaria by mixing an artemisinin-based molecule with one or more fellow drugs. Artemisinin Combination Therapy (ACT) has expanded considerably due to high malaria burden in Southeast Asia and sub-Sahara Africa in the market due to its effectiveness against high malaria burden and drug-resistant Plasmodium Falciparum. Global health initiatives such as WHO guidelines and funding support have improved access and strength. The ongoing drug progress has also increased treatment efficacy and adherence to the patient, collectively increased market growth. Key Growth Drivers and Opportunities Urgent Demand for More Effective Malaria Treatments: A major trend that runs the future of the market is required for more effective malaria remedies between persistent cases and increasing drug resistance. It is promoting innovation in ACT formulations to develop rapid acting, long lasting, and more patient -friendly options. With increased government and international health funding, this progress is improving access and distribution in malaria-sustainable regions, the situation serves as a central solution in the global fight against malaria and promotes strong market development. Challenges Artemisinin combination therapy (ACT) faces boundaries due to the emergence of artemisinin-resistant malaria strains in the market, especially in parts of Southeast Asia. Additionally, inconsistent supply chains, high dependence on donor funding, and limited healthcare infrastructure in some spatial regions obstruct wide access. The need for constant innovation to be ahead of regulator challenges and resistance also leads to the ongoing obstacles for market stability and development. Innovation and Expansion Breakthrough A Treatment for Malaria Without Artemisinin Gives Children Hope In November 2024, Positive findings from KALUMI, a Phase 2 study of a new, non-artemisinin malaria medication combination being developed with Novartis and MMV, have been announced by the West African Network for Clinical Trials of Antimalarial Drugs (WANECAM2) consortium. Given that partial resistance to artemisinin derivatives throughout Africa jeopardizes efforts to eradicate the illness, this is a significant advancement in the fight against malaria. The effectiveness and safety of a combination of lumefantrine, reformulated for once-daily dosage, and ganaplacide, a new drug, were assessed in the KALUMI trial. This novel combination was tested against artemether-lumefantrine, the most popular artemisinin-based combination therapy (ACT) for treating uncomplicated malaria in Africa. Fosun Pharma Acquires USD 3.5M to Promote the Development of Malaria Treatments In December 2023, The Japanese Global Health Innovative Technology (GHIT) Fund has awarded Y500m (USD 3.3m) to China-based Fosun Pharma to further the development of a triple artemisinin combination medication for the treatment of malaria. Artemether, lumefantrine, and amodiaquine are the three antimalarial medications that make up the triple artemisinin combination medication, which comes in a fixed dosage format. The money used to support the Phase III research that looks into the combo treatment. Fosun, the Japanese investment firm Marubini, the Thailand-based research partnership of the universities Mahidol-Oxford Tropical Medicine Research Unit (MORU), and the product development partnership Medicines for Malaria Venture (MMV) will all work together to undertake the III trial. Novartis Provides One Billion Antimalarial Treatment Courses Globally In May 2021, Novartis declared that since 1999, it has provided one billion antimalarial therapy sessions. Over 90% of this artemisinin-based combination treatment (ACT) was given to malaria-endemic nations worldwide at no profit. The most lethal kind of malaria, P. falciparum, which accounts for more than 99% of cases in Africa and half of those in Asia, is treated with ACTs as the standard of care2. ACTs have revolutionized the treatment of malaria since the turn of the century and helped to significantly lower the number of malaria-related fatalities. Inventive Sparks, Expanding Markets Among the leading companies for artemisinin combination therapy are Novartis AG, Cipla, Bliss GVS, and KPC Pharmaceuticals, Inc. The artemisinin combination therapy (ACT) firm is focusing on developing more effective and affordable formulations, such as drug-resistant and kid-safe variants, in order to enhance treatment outcomes and accessibility. Working with governments and international health organizations is another important strategy to expand distribution in malaria-endemic areas. To ensure consistent availability, local production and supply linkages are also reinforced. These programs support global efforts to eradicate malaria, combat medication resistance, and improve patient compliance. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS